Evonile Pharma Reports Q2 FY27 Results Post-ChrysCapital Acquisition

Evonile Pharma (formerly Novartis India) announced its unaudited financial results for Q2 FY27, marking its first reporting period after ChrysCapital acquired a 70.68% stake. The company reported revenue from operations of ₹356.1 crore and an operating EBITDA of -₹31.8 crore, attributed to one-time transition costs and upfront investments. For H1 FY27, revenue was ₹159.9 crore with a Profit after Tax of -₹345.3 crore. Evonile Pharma has focused on building an independent distribution and commercial platform, expanding into cardiology and ophthalmology through strategic acquisitions like Minipress XL and an in-licensing agreement. The company aims to establish itself as a leading branded-generics platform in India.